Remove 2029 Remove Competition Remove Leads
article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029.

Marketing 110
article thumbnail

Securing Europe’s competitiveness in life sciences

European Pharmaceutical Review

Nathalie Moll, Director General, the European Federation of Pharmaceutical Industries and Associations (EFPIA), has commended inclusion of a “dedicated life sciences strategy” in the Political Guidelines for the Next European Commission 2024-2029. As such, she noted that the initial priority will be “prosperity and competitiveness.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. trillion in the Q1 of 2023 to $3.56

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

article thumbnail

Market cap downturn hits over half of top 20 biopharmaceutical companies in Q1 2023

Pharmaceutical Technology

million by 2029. Although Sanofi may face generic drug competition this year for its multiple sclerosis drug, Aubagio, the company is expected to maintain their sales of Dupixent, accounting for 43.3% Johnson & Johnson maintained its leading position despite a decline of 12.8%

article thumbnail

Guide to the AI Tools for Sales to Optimize Performance in 2023

Quantified

through 2029. Competitive pressure will drive companies to invest in AI tools for sales. Use Cases for AI Tools for Sales The sales cycle is often divided into seven stages, from lead generation to completing a sale. Once a list is compiled, the qualification process begins to determine which of the leads are possible prospects.

Sales 52
article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 98